Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12
MWN-AI** Summary
**Capricor Therapeutics to Present Financial Results and Corporate Update on March 12, 2026**
Capricor Therapeutics (NASDAQ: CAPR), a San Diego-based biotechnology firm, is set to release its fourth quarter and full year financial results for 2025 after market close on March 12, 2026. The company focuses on developing innovative cell and exosome-based therapeutics aimed at treating rare diseases, with a particular emphasis on Duchenne muscular dystrophy (DMD). Shortly after the financial release, at 4:30 p.m. ET, Capricor will host a conference call and webcast to discuss the results and provide a recent corporate update. Interested parties can participate via a toll-free number or through a live webcast link, with a replay available afterward in the Investors section of Capricor's website.
At the forefront of Capricor's pipeline is Deramiocel, an allogeneic cardiac-derived cell therapy currently in late-stage development for DMD. The therapy has shown promising preclinical and clinical results, demonstrating immunomodulatory and anti-fibrotic properties that may help maintain cardiac and skeletal muscle functionality in patients. Furthermore, Capricor is advancing its proprietary StealthX™ platform, which is designed for specific therapeutic delivery systems, including vaccine development and targeted delivery of oligonucleotides, proteins, and small molecules.
Capricor underscores its commitment to pioneering rare disease treatments through innovative biotechnological solutions. However, as a forward-looking entity, the company cautions investors about potential risks and uncertainties that could affect its operational outcomes and regulatory progress. This important financial update comes as Capricor seeks to solidify its standing in the competitive biotechnology landscape while striving to bring transformative therapies to market for those in need. More information about the event and Capricor’s initiatives can be found on their official website.
MWN-AI** Analysis
As Capricor Therapeutics (NASDAQ: CAPR) prepares to release its financial results for the fourth quarter and full year of 2025 on March 12, 2026, investors should be attuned to the nuances of this emerging biotechnology firm. At the forefront of its pipeline is Deramiocel, an allogeneic cell therapy for Duchenne muscular dystrophy (DMD), which is poised to make significant waves in the rare disease therapeutic landscape. With recent collaborations, including a commercialization agreement with Nippon Shinyaku for the U.S. and Japan, Capricor has fortified its market position, should regulatory approvals pan out favorably.
Investors should pay close attention to the upcoming conference call, which provides an opportunity for management to outline both financial performance and strategic direction. Key metrics to watch will include research and development expenditures, cash runway estimates, and insights into ongoing clinical trials for Deramiocel and the proprietary StealthX™ platform, which targets delivery mechanisms for various therapeutic applications.
Given the highly competitive biotechnology field, success hinges not just on clinical results, but also on Capricor’s ability to effectively communicate its value proposition to stakeholders. The potential market for DMD therapeutics is substantial, and a successful launch could dramatically enhance revenue potential.
From a market perspective, short-term volatility may occur as investors react to trial results and guidance shared during the call. Long-term investors may find value in Capricor’s innovative approach and strong pipeline, especially if the company can provide clear milestones for product development.
As a high-risk, high-reward stock, Capricor Therapeutics could be an intriguing addition for investors with a tolerance for volatility and a belief in the transformative potential of biotechnology. Keep an eye on the press release on March 12 to inform your investment decisions regarding Capricor.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET –
SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on Thursday, March 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.
| Title: | Capricor Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Thursday, March 12, 2026 |
| Time: | 4:30 p.m. ET |
| Call Details: | Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 70035 Participants may dial in using the numbers above and ask to be joined to the call or click the Call me™ link for instant telephone access to the event. |
| Webcast: | Webcast – Click Here |
A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel’s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX™ platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 26, 2025, and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as filed with the Securities and Exchange Commission on November 10, 2025. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to regulatory approval. Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Raquel Cona
KCSA Strategic Communications
rcona@kcsa.com
212.896.1204
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
FAQ**
What key financial highlights for Capricor Therapeutics Inc. CAPR can investors expect to learn during the conference call regarding the fourth quarter and full year results ended December 32025?
How has Capricor Therapeutics Inc. CAPR's lead product candidate, Deramiocel, progressed in its late-stage development for Duchenne muscular dystrophy (DMD) since the previous financial results report?
What insights about the timeline for regulatory approvals and future clinical trials will Capricor Therapeutics Inc. CAPR provide during the upcoming conference call?
Can Capricor Therapeutics Inc. CAPR elaborate on its partnership with Nippon Shinyaku Co., Ltd. and how it may impact the commercialization strategy for Deramiocel in the U.S. and Japan?
**MWN-AI FAQ is based on asking OpenAI questions about Capricor Therapeutics Inc. (NASDAQ: CAPR).
NASDAQ: CAPR
CAPR Trading
14.86% G/L:
$30.54 Last:
1,739,137 Volume:
$30.77 Open:
